ESMO 2018 | Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide

Name: Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide
Uploaded: 2018-10-19T00:00:00.000Z
Duration: 1 min 52 s

Alison Birtle • 19 Oct 2018

ESMO 2018

Genitourinary Cancer Prostate Cancer Abiraterone Cabazitaxel Enzalutamide

Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, discusses the sequencing of drugs in metastatic castration-resistant prostate cancer. Excitingly, the first prospective study to assess sequencing in this disease space (NCT02254785) was presented on the first day of at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany (Kim Chi, et al.). Dr Birtle discusses the sequencing of cabazitaxel, abiraterone or enzalutamide in this study, and highlights the promising data that was reported for the study endpoints.